Reaching the Fifth Dose on Mounjaro: What to Expect

Why the fifth dose is a decision point, not just the next injection

Mounjaro is supplied as a pre-filled KwikPen, and each pen delivers exactly four weekly doses. That arithmetic means dose five is always the first injection from a new pen. For many people on the standard titration schedule, that new pen arrives at a higher strength, 5mg following four weeks at 2.5mg, 7.5mg following four weeks at 5mg, and so on through the six available UK strengths up to 15mg. But the calendar is a rough guide, not a rule.

What actually matters at this point is how your body has responded. If nausea, vomiting or other gastrointestinal effects were significant during the first four doses, a prescriber may recommend staying at the current strength for another four weeks before stepping up. That is not a setback; it is the titration working as intended. The starting doses exist to settle your system gradually, and there is no clinical prize for reaching 7.5mg on day 29 if you spent week three feeling rough.

The Mounjaro dose structure is designed around tolerability precisely because most side effects cluster around the first few weeks at each new strength. Knowing that in advance makes the fifth-dose decision feel less like a cliff edge and more like a planned checkpoint. If you are uncertain what your prescriber has recommended, the patient information leaflet inside your pen pack is the first place to check, and your clinical team is the right person to ask.

What changes (and what stays the same) when you move to a new strength

The pen itself looks identical. What you receive in the plain, unbranded box is the same KwikPen format, with the same single weekly injection process. The difference is the concentration inside: the drug is tirzepatide, a dual GIP and GLP-1 receptor agonist, and a higher dose means a stronger signal to those two pathways involved in appetite regulation and gastric emptying. For context on how those mechanisms compare with other treatments, the weight-loss treatment overview covers the field clearly.

The practical question most people have is whether side effects restart when the strength increases. Often, yes, to a milder degree. The gastrointestinal effects that settled after week two or three of 2.5mg can resurface briefly when you start 5mg, then again at 7.5mg. Eating smaller portions, staying well hydrated and avoiding fatty meals helps most people manage the transition. These effects usually ease within a week or two. If they do not, or if you experience severe, persistent stomach pain (especially any that radiates towards your back) contact a doctor promptly. The MHRA's Drug Safety Update for GLP-1 medicines flags acute pancreatitis as an infrequent but serious possibility that warrants urgent assessment.

It is also worth knowing that appetite suppression tends to become more noticeable at higher strengths. Protein intake, hydration and keeping some physical activity going all matter more, not less, as doses increase. Your prescriber or a dietitian is the right person to guide the specifics, not a dose calculator found online.

When staying at 5mg for a fifth dose (and beyond) is the right call

Not everyone follows an every-four-weeks step-up. Some people tolerate the titration quickly and feel their prescriber is right to move them along; others do better holding a dose for eight weeks before advancing. Both are clinically valid. If you want to understand what to expect at this level, our guide to the Mounjaro 5mg dose explains what the strength involves and why some people stay at it longer than the standard four weeks, and people who do are not doing Mounjaro wrong.

There is also a ceiling. If someone reaches the highest tolerated dose and loses less than 5% of body weight after six months, NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed. That is a conversation for a prescriber, not a self-assessment. The relevant NICE guidance on tirzepatide is publicly available for anyone who wants to read the full recommendation.

For people asking about cost as they move between pens, the Mounjaro price comparison page sets out what UK private treatment typically costs across different providers and strengths, including what headline prices sometimes leave out. What should never change, regardless of which pen you are opening, is the fact that a prescriber is reviewing your treatment before the next one arrives. At nume, that review happens personally, on the same day you request a repeat, before anything is dispensed.

How to handle practical questions about your fifth dose

A few things come up repeatedly at this stage. The most common: what if the fifth dose arrives but you are not sure whether to use it at the new strength? The answer is simple, do not change strength without your prescriber's confirmation. Use the dose you have been prescribed. If your pen ran out and a new one has not arrived, contact your clinical team rather than skipping the injection or splitting doses across the week. The four-dose pen guide explains the pen format in detail, which helps avoid confusion about how many injections remain.

Some people ask whether the fifth dose can be taken at a different interval, either to catch up or to spread out side effects. Timing adjustments are a question for your prescriber; the patient information leaflet gives the full schedule, and the nume FAQs cover the most frequent practical queries. For anything specific to your own history, the support team is available seven days a week.

If you are not yet on Mounjaro and wondering whether it is right for you, our prescribers review consultations personally. Check your eligibility and start a free consultation to find out whether treatment is clinically appropriate for you.